BAFF inhibition: A new class of drugs for the treatment of autoimmunity

Experimental Cell Research

Volumn 317, Issue 9, 2011, Pages 1270-1277

  Liu, Zheng ^a   Davidson, Anne ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Autoimmunity; B cells; BAFF; Systemic lupus erythematosus

Indexed keywords

APRIL PROTEIN; ATACICEPT; AUTOANTIBODY; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR INHIBITOR; B CELL ACTIVATING FACTOR RECEPTOR; B LYMPHOCYTE RECEPTOR; BELIMUMAB; CYTOKINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; NEW DRUG; STEROID; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIBODY TITER; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CELL SURVIVAL; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; EFFECTOR CELL; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; INFECTION RISK; INNATE IMMUNITY; LEUKOCYTE; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

MUS;

EID: 79955673217     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2011.02.005     Document Type: Review

References (58)

1. Mackay F., Schneider P. Cracking the BAFF code. Nat. Rev. Immunol. 2009, 9:491-502.
2. Gross J.A., Johnston J., Mudri S., Enselman R., Dillon S.R., Madden K., Xu W., Parrish-Novak J., Foster D., Lofton-Day C., Moore M., Littau A., Grossman A., Haugen H., Foley K., Blumberg H., Harrison K., Kindsvogel W., Clegg C.H. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000, 404:995-999.
3. Ramanujam M., Wang X., Huang W., Liu Z., Schiffer L., Tao H., Frank D., Rice J., Diamond B., Yu K.O., Porcelli S., Davidson A. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J. Clin. Invest. 2006, 116:724-734.
4. Dall'Era M., Chakravarty E., Wallace D., Genovese M., Weisman M., Kavanaugh A., Kalunian K., Dhar P., Vincent E., Pena-Rossi C., Wofsy D. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007, 56:4142-4150.
5. Tak P.P., Thurlings R.M., Rossier C., Nestorov I., Dimic A., Mircetic V., Rischmueller M., Nasonov E., Shmidt E., Emery P., Munafo A. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum. 2008, 58:61-72.
6. Pena-Rossi C., Nasonov E., Stanislav M., Yakusevich V., Ershova O., Lomareva N., Saunders H., Hill J., Nestorov I. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus 2009, 18:547-555.
7. Nestorov I., Munafo A., Papasouliotis O., Visich J. Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis. J. Clin. Pharmacol. 2008, 48:406-417.
8. Moore P.A., Belvedere O., Orr A., Pieri K., LaFleur D.W., Feng P., Soppet D., Charters M., Gentz R., Parmelee D., Li Y., Galperina O., Giri J., Roschke V., Nardelli B., Carrell J., Sosnovtseva S., Greenfield W., Ruben S.M., Olsen H.S., Fikes J., Hilbert D.M. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999, 285:260-263.
9. Schneider P., MacKay F., Steiner V., Hofmann K., Bodmer J.L., Holler N., Ambrose C., Lawton P., Bixler S., Acha-Orbea H., Valmori D., Romero P., Werner-Favre C., Zubler R.H., Browning J.L., Tschopp J. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J. Exp. Med. 1999, 189:1747-1756.
10. Yu G., Boone T., Delaney J., Hawkins N., Kelley M., Ramakrishnan M., McCabe S., Qiu W.R., Kornuc M., Xia X.Z., Guo J., Stolina M., Boyle W.J., Sarosi I., Hsu H., Senaldi G., Theill L.E. APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat. Immunol. 2000, 1:252-256.
11. Kayagaki N., Yan M., Seshasayee D., Wang H., Lee W., French D.M., Grewal I.S., Cochran A.G., Gordon N.C., Yin J., Starovasnik M.A., Dixit V.M. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity 2002, 17:515-524.
12. Bossen C., Cachero T.G., Tardivel A., Ingold K., Willen L., Dobles M., Scott M.L., Maquelin A., Belnoue E., Siegrist C.A., Chevrier S., Acha-Orbea H., Leung H., Mackay F., Tschopp J., Schneider P. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood 2008, 111:1004-1012.
13. Claudio E., Brown K., Park S., Wang H., Siebenlist U. BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat. Immunol. 2002, 3:958-965.
14. Hatada E.N., Do R.K., Orlofsky A., Liou H.C., Prystowsky M., MacLennan I.C., Caamano J., Chen-Kiang S. NF-kappa B1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NF-kappa B2 p100 to p52 in quiescent mature B cells. J. Immunol. 2003, 171:761-768.
15. Mackay F., Figgett W.A., Saulep D., Lepage M., Hibbs M.L. B-cell stage and context-dependent requirements for survival signals from BAFF and the B-cell receptor. Immunol. Rev. 2010, 237:205-225.
16. Tangye S.G., Bryant V.L., Cuss A.K., Good K.L. BAFF, APRIL and human B cell disorders. Semin. Immunol. 2006, 18:305-317.
17. Bossen C., Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 2006, 18:263-275.
18. Castigli E., Wilson S.A., Scott S., Dedeoglu F., Xu S., Lam K.P., Bram R.J., Jabara H., Geha R.S. TACI and BAFF-R mediate isotype switching in B cells. J. Exp. Med. 2005, 201:35-39.
19. Mackay F., Schneider P. TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties. Cytokine Growth Factor Rev. 2008, 19:263-276.
20. Gavin A.L., Ait-Azzouzene D., Ware C.F., Nemazee D. DeltaBAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine, BAFF. J. Biol. Chem. 2003, 278:38220-38228.
21. Gavin A.L., Duong B., Skog P., Ait-Azzouzene D., Greaves D.R., Scott M.L., Nemazee D. {Delta}BAFF, a splice isoform of BAFF, opposes full-length BAFF activity in vivo in transgenic mouse models. J. Immunol. 2005, 175:319-328.
22. Jeon S.T., Kim W.J., Lee S.M., Lee M.Y., Park S.B., Lee S.H., Kim I.S., Suk K., Choi B.K., Choi E.M., Kwon B.S., Lee W.H. Reverse signaling through BAFF differentially regulates the expression of inflammatory mediators and cytoskeletal movements in THP-1 cells. Immunol. Cell Biol. 2010, 88:148-156.
23. Diaz-de-Durana Y., Mantchev G.T., Bram R.J., Franco A. TACI-BLyS signaling via B-cell-dendritic cell cooperation is required for naive CD8+ T-cell priming in vivo. Blood 2006, 107:594-601.
24. Stadanlick J.E., Kaileh M., Karnell F.G., Scholz J.L., Miller J.P., Quinn W.J., Brezski R.J., Treml L.S., Jordan K.A., Monroe J.G., Sen R., Cancro M.P. Tonic B cell antigen receptor signals supply an NF-kappaB substrate for prosurvival BLyS signaling. Nat. Immunol. 2008, 9:1379-1387.
25. Thien M., Phan T.G., Gardam S., Amesbury M., Basten A., Mackay F., Brink R. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004, 20:785-798.
26. Lesley R., Xu Y., Kalled S.L., Hess D.M., Schwab S.R., Shu H.B., Cyster J.G. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004, 20:441-453.
27. Boule M.W., Broughton C., Mackay F., Akira S., Marshak-Rothstein A., Rifkin I.R. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J. Exp. Med. 2004, 199:1631-1640.
28. Treml L.S., Carlesso G., Hoek K.L., Stadanlick J.E., Kambayashi T., Bram R.J., Cancro M.P., Khan W.N. TLR stimulation modifies BLyS receptor expression in follicular and marginal zone B cells. J. Immunol. 2007, 178:7531-7539.
29. Katsenelson N., Kanswal S., Puig M., Mostowski H., Verthelyi D., Akkoyunlu M. Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion. Eur. J. Immunol. 2007, 37:1785-1795.
30. Groom J.R., Fletcher C.A., Walters S.N., Grey S.T., Watt S.V., Sweet M.J., Smyth M.J., Mackay C.R., Mackay F. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J. Exp. Med. 2007, 204:1959-1971.
31. Rahman Z.S., Rao S.P., Kalled S.L., Manser T. Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice. J. Exp. Med. 2003, 198:1157-1169.
32. Kalled S.L. Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody production. Semin. Immunol. 2006, 18:290-296.
33. Avery D.T., Kalled S.L., Ellyard J.I., Ambrose C., Bixler S.A., Thien M., Brink R., Mackay F., Hodgkin P.D., Tangye S.G. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J. Clin. Invest. 2003, 112:286-297.
34. Benson M.J., Dillon S.R., Castigli E., Geha R.S., Xu S., Lam K.P., Noelle R.J. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J. Immunol. 2008, 180:3655-3659.
35. Doreau A., Belot A., Bastid J., Riche B., Trescol-Biemont M.C., Ranchin B., Fabien N., Cochat P., Pouteil-Noble C., Trolliet P., Durieu I., Tebib J., Kassai B., Ansieau S., Puisieux A., Eliaou J.F., Bonnefoy-Berard N. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat. Immunol. 2009, 10:778-785.
36. Ettinger R., Kuchen S., Lipsky P.E. The role of IL-21 in regulating B-cell function in health and disease. Immunol. Rev. 2008, 223:60-86.
37. Wallace D.J., Stohl W., Furie R.A., Lisse J.R., McKay J.D., Merrill J.T., Petri M.A., Ginzler E.M., Chatham W.W., McCune W.J., Fernandez V., Chevrier M.R., Zhong Z.J., Freimuth W.W. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009, 61:1168-1178.
38. Belnoue E., Pihlgren M., McGaha T.L., Tougne C., Rochat A.F., Bossen C., Schneider P., Huard B., Lambert P.H., Siegrist C.A. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 2008, 111:2755-2764.
39. Mohr E., Serre K., Manz R.A., Cunningham A.F., Khan M., Hardie D.L., Bird R., MacLennan I.C. Dendritic cells and monocyte/macrophages that create the IL-6/APRIL-rich lymph node microenvironments where plasmablasts mature. J. Immunol. 2009, 182:2113-2123.
40. Scholz J.L., Crowley J.E., Tomayko M.M., Steinel N., O'Neill P.J., Quinn W.J., Goenka R., Miller J.P., Cho Y.H., Long V., Ward C., Migone T.S., Shlomchik M.J., Cancro M.P. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc. Natl Acad. Sci. USA 2008, 105:15517-15522.
41. Yang M., Sun L., Wang S., Ko K.H., Xu H., Zheng B.J., Cao X., Lu L. Novel function of B cell-activating factor in the induction of IL-10-producing regulatory B cells. J. Immunol. 2010, 184:3321-3325.
42. Kimberley F.C., Hahne M., Medema J.P. "APRIL hath put a spring of youth in everything": relevance of APRIL for survival. J. Cell. Physiol. 2009, 218:1-8.
43. Lai Kwan Lam Q., King Hung Ko O., Zheng B.J., Lu L. Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis. Proc. Natl Acad. Sci. USA 2008, 105:14993-14998.
44. Scapini P., Hu Y., Chu C.L., Migone T.S., Defranco A.L., Cassatella M.A., Lowell C.A. Myeloid cells, BAFF, and IFN-{gamma} establish an inflammatory loop that exacerbates autoimmunity in Lyn-deficient mice. J. Exp. Med. 2010.
45. Chang S.K., Mihalcik S.A., Jelinek D.F. B lymphocyte stimulator regulates adaptive immune responses by directly promoting dendritic cell maturation. J. Immunol. 2008, 180:7394-7403.
46. Ramanujam M., Davidson A. BAFF blockade for systemic lupus erythematosus-will the promise be fulfilled?. Immunol. Rev. 2008, 223:156-174.
47. Ramanujam M., Bethunaickan R., Huang W., Tao H., Madaio M.P., Davidson A. Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice. Arthritis Rheum. 2010, 62:1457-1468.
48. Jacob C.O., Pricop L., Putterman C., Koss M.N., Liu Y., Kollaros M., Bixler S.A., Ambrose C.M., Scott M.L., Stohl W. Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF. J. Immunol. 2006, 177:2671-2680.
49. Liu W., Szalai A., Zhao L., Liu D., Martin F., Kimberly R.P., Zhou T., Carter R.H. Control of spontaneous B lymphocyte autoimmunity with adenovirus-encoded soluble TACI. Arthritis Rheum. 2004, 50:1884-1896.
50. Ju Z.L., Shi G.Y., Zuo J.X., Zhang J.W. Unexpected development of autoimmunity in BAFF-R-mutant MRL-lpr mice. Immunology 2007, 120:281-289.
51. Ramanujam M., Wang X., Huang W., Schiffer L., Grimaldi C., Akkerman A., Diamond B., Madaio M.P., Davidson A. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J. Immunol. 2004, 173:3524-3534.
52. Kahn P., Ramanujam M., Bethunaickan R., Huang W., Tao H., Madaio M.P., Factor S.M., Davidson A. Prevention of murine antiphospholipid syndrome by BAFF blockade. Arthritis Rheum. 2008, 58:2824-2834.
53. Jacobi A.M., Huang W., Wang T., Freimuth W., Sanz I., Furie R., Mackay M., Aranow C., Diamond B., Davidson A. Effect of long-term belimumab treatment on b cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2010, 62:201-210.
54. P.P. Tak, R.M. Thurlings, A. Dimic, V. Mircetic, M. Rishmueller, E. Nasanov, E. Shmidt, P. Emery, C. Rossier, I. Nesterov, J. Hill, A. Munafo, A Phase Ib study to investigate Atacicept (TACI-Ig) in patients with rheumatoid arthritis., ACR/ARHP Meeting Scientific Meeting, (late breaking abstract), Washington, DC., 2006.
55. Ginzler E., Furie R., Wallace D.J., Strand V., Lisse J., Stohl W., Merrill J.T., Petri M., Aranow C., Weinstein A., Fernandez V., Zhong J., Freimuth W. Novel combined response endpoint shows that belimumab (fully human monoclonal antibody to B-lymphocyte stimulator [BLyS]) improves or stabilizes SLE disease activity in a phase 2 trial. EULAR 2007.
56. Seyler T.M., Park Y.W., Takemura S., Bram R.J., Kurtin P.J., Goronzy J.J., Weyand C.M. BLyS and APRIL in rheumatoid arthritis. J. Clin. Invest. 2005, 115:3083-3092.
57. Krumbholz M., Theil D., Derfuss T., Rosenwald A., Schrader F., Monoranu C.M., Kalled S.L., Hess D.M., Serafini B., Aloisi F., Wekerle H., Hohlfeld R., Meinl E. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J. Exp. Med. 2005, 201:195-200.
58. Huntington N.D., Tomioka R., Clavarino C., Chow A.M., Linares D., Mana P., Rossjohn J., Cachero T.G., Qian F., Kalled S.L., Bernard C.C., Reid H.H. A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses. Int. Immunol. 2006, 18:1473-1485.